A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF+ cells.
In this study, a recombinant truncated West Nile virus envelope protein antigen (rWNV-E) was produced in serum-free cultures of the expresSF+ insect cell line via baculovirus infection. This production system was selected based on its use in the production of candidate human and animal vaccine antigens. A defined fermentation and purification process for the rWNV-E antigen was established to control for purity and immunogenicity of each protein batch. The material formulated with aluminum hydroxide was stable for greater than 8months at 4 degrees C. The recombinant vaccine candidate was evaluated for immunogenicity and protective efficacy in several animal models. In mouse and hamster WNV challenge models, the vaccine candidate induced viral protection that correlated with anti-rWNV-E immunogenicity and WNV neutralizing antibody titers. The rWNV-E vaccine candidate was used to boost horses previously immunized with the Fort Dodge inactivated WNV vaccine and also to induce WNV neutralizing titers in naïve foals that were at least 14weeks of age. Furthermore, the vaccine candidate was found safe when high doses were injected into rats, with no detectable treatment-related clinical adverse effects. These observations demonstrate that baculovirus-produced rWNV-E can be formulated with aluminum hydroxide to produce a stable and safe vaccine which induces humoral immunity that can protect against WNV infection.
Bonafé
Nathalie
N
L2 Diagnostics, LLC, 300 George Street, New Haven, CT 06511, USA. nathalie.bonafe@L2dx.com
Rininger
Joseph A
JA
Chubet
Richard G
RG
Foellmer
Harald G
HG
Fader
Stacey
S
Anderson
John F
JF
Bushmich
Sandra L
SL
Anthony
Karen
K
Ledizet
Michel
M
Fikrig
Erol
E
Koski
Raymond A
RA
Kaplan
Paul
P
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D016367:Baculoviridae / Q000235:genetics / Q000378:metabolism; D002478:Cells, Cultured; D006224:Cricetinae; D004195:Disease Models, Animal; D006734:Horse Diseases / Q000276:immunology / Q000517:prevention & control / Q000821:virology; D006736:Horses; D006801:Humans; D051379:Mice; D051381:Rats; D011994:Recombinant Proteins / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D018411:Spodoptera / Q000378:metabolism* / Q000821:virology; D014759:Viral Envelope Proteins / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D014901:West Nile Fever / Q000276:immunology / Q000517:prevention & control*; D053060:West Nile Virus Vaccines / Q000008:administration & dosage / Q000276:immunology / Q000378:metabolism*; D014902:West Nile virus / Q000235:genetics / Q000276:immunology*
D000914:Antibodies, Viral; D011994:Recombinant Proteins; D014759:Viral Envelope Proteins; D053060:West Nile Virus Vaccines